You searched for "regulation"

826 results found

HIV / AIDS – implications for the urologist

“It’s no fun to have HIV even though it’s viewed as a chronic, controllable disease. It means being wedded to the health system.” - Philip Berger, Associate Professor in the Department of Family and Community Medicine, Toronto, Canada; and leading...

The role of embolisation in urology

Case 1 An 86–year–old male presented with visible haematuria and suprapubic pain. He had a history of diabetes, heart failure, benign prostatic hypertrophy, aortic valve replacement, deep vein thrombosis (DVT) and atrial fibrillation (AF) and was anticoagulated on a non-VKA...

Joaquín Albarrán (1860–1912), the gifted promise

In this series of articles, I am going to show you some of the exhibits contained in the Museum of Urology, hosted on the BAUS website (www.baus.org.uk). Does the name Joaquín Albarrán mean anything to you? Maybe you remember using...

Male infertility?

Diagnose Sperm Oxidative Stress, a major cause of male infertility, using MiOXSYS™

Clitoral reconstructive surgery after female genital cutting

Practised in Africa and other parts of the world, the WHO recently estimated that over 250 million females have been circumcised so far, and an additional three million are at risk of circumcision each year...

TPTNS: evaluation of a therapeutic option in the management of anticholinergic refractory overactive bladder

This is a prospective study evaluating the tolerability and efficacy of transcutaneous posterior tibial nerve stimulation (TPTNS) in patients with urodynamically proven overactive bladder (OAB), who have failed anticholinergic treatment. Forty-three patients were studied and followed up over a period...

BCG after TURBT – does timing matter?

Intravesical bacille Calmette–Guerin (BCG) therapy continues to be widely used for patients with intermediate / high-risk non-muscle invasive bladder cancer (NMIBC). In this article, the researchers identified the lack of sufficient evidence with regards to timing of BCG after transurethral...

Long-term complications of bulking agents in the treatment of SUI

Incontinence poses a substantial economic burden on the UK’s NHS, estimated at £536 million in 1999/2000, equivalent to approximately 1.1% of the total NHS spend, for both men and women. Over two decades later, this cost is expected to have...

Goddard’s Dropps: a Paradox of the C17th

In this series of articles I am going to show you some of the exhibits contained in the Museum of Urology, hosted on the BAUS website (www.baus.org.uk). In the last article I told you about the world of the London...

The assessment and medical treatment of LUTS secondary to BPH

The term benign prostatic hyperplasia (BPH) describes prostate enlargement due to non-cancerous processes. Several aetiological mechanisms are involved, including hormonal and vascular alterations; abnormal regulation of apoptosis; and prostatic inflammation, which may stimulate cellular proliferation. With ageing, prostate enlargement can...

Update on immunotherapy for non-muscle invasive transitional cell carcinoma of the bladder

Patients with high-risk non-muscle invasive bladder cancer (NMIBC) that have failed Bacillus Calmette-Guérin (BCG) treatment are a difficult group to treat, and many may not be suitable for the preferred treatment option of radical cystectomy. Bladder-preserving treatments for BCG-unresponsive high-risk...

Pushing the boundaries of urological research with trainee-led collaboration in the BURST Research Collaborative

Background: the concept of trainee-led research Over the past five years a novel and exciting collaborative approach to delivering research has been developed in the UK. Trainee-led regional and national research networks have been introduced, with the greatest success seen...